ASCO 2023 | I-SPY 2: immunotherapy biomarkers in early breast cancer

Denise M. Wolf, MD, PhD, University of California, San Fransisco, CA, discusses an evaluation of immune subtyping in the response predictive subtypes (RPS) in the Phase II I-SPY2 (NCT01042379) trial designed to improve outcomes in patients with high-risk breast cancer. Immune markers were evaluated in five immune-oncology (IO) therapy arms, including PD1-inhibitor and PDL1-inhibitor combinations. Tumor-immune signatures dominated by chemokines/cytokines were consistently associated with pathological complete response (pCR) across all IO arms and receptor statuses. Research-grade immune markers predicted response to IO more in hormone receptor-positive (HR+) than in triple-negative breast cancer (TNBC). The ImPrint classifier, which assesses immune signatures, showed promising performance in predicting pCR rates across different IO arms and HR subsets. This study highlights the potential of immune biomarkers to predict IO therapy response and may aid in treatment prioritization and balancing benefits with immune-related adverse events. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.